Holen Sie sich die Stockscreener-App
174.63
0.97%
1.68
Handel nachbörslich:
175.00
0.37
+0.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$172.95
Offen:
$172.8
24-Stunden-Volumen:
1.91M
Relative Volume:
0.67
Marktkapitalisierung:
$49.98B
Einnahmen:
$20.87B
Nettoeinkommen (Verlust:
$1.50B
KGV:
33.33
EPS:
5.24
Netto-Cashflow:
$2.59B
1W Leistung:
-1.71%
1M Leistung:
+0.68%
6M Leistung:
-25.51%
1J Leistung:
-22.57%
1-Tages-Spanne:
$172.50
$175.65
1-Wochen-Bereich:
$172.34
$178.30
52-Wochen-Spanne:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Vergleichen Sie BDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
174.63 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
527.30 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
87.05 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.59 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
220.48 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
YieldBoost Becton, Dickinson From 2.5% To 15.5% Using Options - Nasdaq
BD upgrades laboratory in Suzhou - China Daily
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift - Investing.com
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift By Investing.com - Investing.com India
Becton Dickinson Stock Price, Quotes and Forecasts | NYSE:BDX - Benzinga
Medical technology firm BD looks to bring products to more PHL hospitals - BusinessWorld Online
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead By Investing.com - Investing.com South Africa
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead - Investing.com Australia
Becton, Dickinson And Co To Present At Goldman Sachs Conference; Webcast At 2:00 PM ET - Nasdaq
Stifel maintains Becton Dickinson stock with a $224 target - Investing.com
Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock - Yahoo Finance
Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating - MSN
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
BD’s Future Plans: Shed Life Sciences to Fund Medical Technology - Lab Manager
How Is Becton, Dickinson and Company’s Performance Compared to Other Medical Instruments & Supplies Stocks? - Barchart.com
Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus
Barclays lowers Becton Dickinson stock price target to $241 By Investing.com - Investing.com South Africa
Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com
Barclays lowers Becton Dickinson stock price target to $241 - Investing.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barcl - GuruFocus
Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus
Becton Dickinson EVP David Shan Sells Shares and Other Important Updates - TradingView
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - Becton Dickinson
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
Employees return to work at North Canaan plant where suspicious package was delivered, officials say - CT Insider
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Health dept. clears BD to reopen facility after hazmat scare - The Lakeville Journal
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):